

Sisram Medical Announces Share Repurchase Plan for Up to 1% of Issued Shares

Reinforcing Confidence in Long-Term Growth and Commitment to Shareholder Returns

HONG KONG, October 8, 2026 -- Sisram Medical Ltd (the “**Company**” or “**Sisram**”, 1696.HK), a global wellness group offering Energy-Based Devices (“EBD”), injectables, and other complementary solutions, today announced a share repurchase plan under its existing share repurchase mandate and subject to market conditions. Sisram intends to repurchase shares in the open market, up to 1% of its total issued shares. Repurchased shares may either be cancelled or held as treasury shares, depending on the Company’s subsequent capital management needs.

The share repurchase reflects the Board of Directors’ and management’s confidence in Sisram’s business fundamentals and long-term prospects, while underscoring the Company’s ongoing commitment to shareholder returns and long-term value creation. Sisram will implement the plan in a prudent and disciplined manner, balancing business development, strategic investment priorities, financial flexibility, and prevailing market conditions. The Company will also assess shareholder return measures that are appropriate to its stage of development and capital allocation priorities, with the aim of sharing the benefits of its growth with shareholders.

In the first half of 2026, Sisram delivered steady business progress, with revenue reaching US\$171.4 million, up 3.6% year on year (“YoY”). Revenue from international markets (excluding North America) rose 16.7% YoY to US\$127.0 million. APAC stood out as a key driver of international growth, generating US\$78.4 million in revenue, an increase of 19.1% YoY. The injectables business maintained robust momentum, with revenue rising 54.2% YoY to US\$22.2 million and accounting for 12.9% of total revenue, cementing its position as the Company’s second growth engine.

Operational momentum was also evident across Sisram’s core businesses. In the EBD business, flagship platforms including Alma Harmony and Hybrid family sustained solid market traction, while new product rollouts across APAC and localization initiatives in China advanced in tandem. In the injectables business, the commercialization of DAXXIFY in mainland China progressed steadily, while differentiated products including Profhilo and Hallura broadened their presence, further strengthening the foundation for more diversified growth.

Looking ahead, Sisram will further strengthen the strategic integration of R&D and innovation, global commercial operations, and localized capabilities, anchored by its three global strategic hubs in Israel, the United States, and China. The Company will continue to advance the iteration of its core products and the translation of innovation into commercial outcomes, while accelerating the registration and commercialization of key products across major global markets. At the same time, Sisram will actively explore partnerships and strategic growth opportunities that create meaningful synergies with its broader wellness ecosystem. Through a more resilient global operating platform and increasingly diversified growth drivers, the Company aims to build a solid foundation for sustainable long-term growth.

“We are launching this share repurchase after a comprehensive assessment of Sisram’s business performance, financial position and market conditions, reflecting our confidence in the Company’s

long-term prospects and our commitment to sharing the benefits of Sisram's growth with our shareholders," said **Mr. Jiahong Li, Co-CEO and CFO of Sisram**. "Over the past period, we have advanced key strategic priorities across product innovation, strategic market expansion and operational efficiency, reinforcing the competitive foundations of our core businesses. As these initiatives deliver results, we believe the market will increasingly recognize Sisram's long-term value. Looking ahead, we will remain focused on strengthening our core businesses and executing our strategy with discipline, while creating sustainable long-term value for our shareholders."

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD). Built on a legacy of innovation and clinical excellence, the Company's synergistic ecosystem spans EBD technologies, injectables, diagnostics, and complementary solutions. Serving customers in over 110 countries and regions, Sisram delivers award-winning products that set new standards in safety, efficacy, and personalized aesthetic care for millions of patients worldwide. Majority-owned by Fosun Pharma, Sisram has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017.

For more information, please visit: www.sisram-medical.com.

Forward-Looking Statement

The information communicated in this press release contains certain statements that are or may be forward-looking. These statements typically contain words such as "will," "expects," "believes," "plans" and "anticipates," and words of similar import. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company is unaware. These forward-looking statements are not a guarantee of future performance. Against the background of these uncertainties, readers should not rely on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

The implementation of the Share Repurchase Plan will be subject to the Share Repurchase Mandate, applicable provisions of the Company's Articles of Association, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, The Codes on Takeovers and Mergers and Share Buy-backs and other applicable laws and regulations. There is no assurance of the timing, quantity or price of any share repurchases. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

For Investor Relations inquiries, please contact:

IR@sisram-medical.com